Abstract: The present invention relates to a pharmaceutical foam composition comprising a corticosteroid and a Vitamin D analogue for topical administration to a patient in need thereof, such as for the treatment of plaque psoriasis. The present invention also relates to a process for preparing the composition and a suitable container system for administration of the composition. Preferably, the invention relates to the topical administration of betamethasone dipropionate and calcipotriene with one or more pharmaceutically acceptable excipients and propellants where the composition is stable in the container system coated with a coating material selected from the group comprising of epoxyphenol resin, modified polyesters, microflex coating or polyacrylates.

Abstract: The invention relates to metered dose inhaler comprising a stable pharmaceutical composition of fluticasone or its pharmaceutically acceptable ester contained in a canister fitted with a metering valve, an actuator and dose counter. The invention also relates to a process for preparing said pharmaceutical composition and its use in the treatment of respiratory disorders such as asthma in a subject (e.g., a human).

Abstract: The present invention relates to an inhalable composition comprising a therapeutically effective dosage amount of compound (I), 2-{4-[(2S)-1,1-difluoro-2-hydroxypropyl]phenyl}-N-{4-[3-(2-ethylphenyl) pyrazine-2-yl]phenyl}acetamide or a pharmaceutically acceptable salt thereof. Particularly, the present invention relates to a inhalable dry powder composition comprising compound (I) or a pharmaceutically acceptable salt thereof. Further, the present invention relates to a method of treating a pulmonary disease using such a composition.

Abstract: The invention relates to metered dose inhaler comprising a stable pharmaceutical composition of fluticasone or its pharmaceutically acceptable ester contained in a canister fitted with a metering valve, an actuator and dose counter. The invention also relates to a process for preparing said pharmaceutical composition and its use in the treatment of respiratory disorders such as asthma in a subject (e.g., a human).

Abstract: The present invention relates to a pharmaceutical foam composition comprising a corticosteroid and a Vitamin D analogue for topical administration to a patient in need thereof, such as for the treatment of plaque psoriasis. The present invention also relates to a process for preparing the composition and a suitable container system for administration of the composition. Preferably, the invention relates to the topical administration of betamethasone dipropionate and calcipotriene with one or more pharmaceutically acceptable excipients and propellants where the composition is stable in the container system coated with a coating material selected from the group comprising of epoxyphenol resin, modified polyesters, microflex coating or polyacrylates.

Abstract: The present invention relates to a mupirocin topical pharmaceutical composition in a pump device, and its use for dispensing predetermined quantities of mupirocin for treating skin lesions.

Abstract: This disclosure relates to a nebulization composition comprising tiotropium, or a pharmaceutically acceptable salt thereof, and indacaterol, or a pharmaceutically acceptable salt thereof. This disclosure also relates to a process for preparing such a composition and to methods of treating inflammatory and/or obstructive airway diseases using such a composition.

Abstract: The present invention relates to a mupirocin topical pharmaceutical composition in a pump device, and its use for dispensing predetermined quantities of mupirocin for treating skin lesions.

Abstract: This invention provides coated pellets comprising a) a pellet core which comprises venlafaxine hydrochloride; b) a first coating which comprises a lipophilic layer or a sparingly water-soluble layer, and c) a second coating which comprises a water-insoluble polymer or polymer mixture. In another aspect this invention provides compositions which comprises the coated pellets. In a further aspect, the invention provides a process for preparing the coated pellets which process avoids use of organic solvents at least for the second coating.

Abstract: A pharmaceutical composition comprising as an active ingredient an HMG-CoA reductase inhibitor and an aminosugar.

Abstract: A pharmaceutical composition comprising as an active ingredient an HMG-CoA reductase inhibitor and an aminosugar.